Ponderile din venituri sunt estimări pentru 2025, nu cifre dintr-un raport depus.
Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.
Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.
Situațiile financiare complete →
Jazz develops and sells prescription medicines, focusing on rare sleep disorders, epilepsy and cancers. Its largest products include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for seizures linked to certain rare conditions. It also sells cancer medicines and runs clinical trials to test new medicines and uses for existing ones. At September 30, 2026, about 17,550 patients were taking Xywav (high confidence).
Construit din raportările proprii ale Jazz Pharmaceuticals plc la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
240,40 USD-3,1 %închidere 12 nov.
Cifre până la 30 septembrie 2026, din 10-Q depus pe 2 noiembrie 2026
Jazz sells low-sodium oxybate medicine for narcolepsy and idiopathic hypersomnia, plus epilepsy and cancer drugs to patients through pharmacies and hospitals.
Estimarea companiei: venituri de între 4,8B USD și 4,9B USD pentru Anul fiscal 2026 — în creștere cu 12,8 % față de anul anterior
Just reported
From Jazz Pharmaceuticals's results release of 2 noiembrie 2026; its quarterly report has since been filed.
Actual
1,24B USD
+10 % y/y
+2,9 % q/q
Guided
—
No guide given
Actual
-7,48 USD
Guided
—
No guide given
Actual
-413,4M USD
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Jazz Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A
Banda de sub preț arată nota la fiecare dată, calculată doar din documentele publice până atunci.
Se afișează 2 din 41 trimestre din istoricul notelor companiei Jazz Pharmaceuticals plc. Celelalte 39 merg înapoi până în noiembrie 2016.